NCT00394940

Brief Summary

Chronic obstructive pulmonary disease (COPD) is a condition that is characterized by airway obstruction due to inflammation. Levels of inflammatory proteins may be linked to when and to what extent COPD develops. This study will use data collected during the Tucson Epidemiological Study of Airway Obstructive Disease (TESAOD) and its 33-year follow-up to determine the relationship between inflammatory protein expression and COPD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,085

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2006

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2006

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 31, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 2, 2006

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2013

Completed
Last Updated

December 6, 2017

Status Verified

December 1, 2017

Enrollment Period

6.5 years

First QC Date

October 31, 2006

Last Update Submit

December 4, 2017

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPDEmphysemaChronic BronchitisInflammationCD14TLR4Proteomics

Outcome Measures

Primary Outcomes (1)

  • COPD development defined as FEV1/FVC < 70%

    up to 50 years

Secondary Outcomes (2)

  • COPD progression defined based on decline of lung function

    up to 50 years

  • Mortality

    up to 50 years

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Sample of the general population that was enrolled in 1972

You may qualify if:

  • Enrolled in the Tucson Epidemiological Study of Airway Obstructive Disease (TESAOD)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Arizona Respiratory Center

Tucson, Arizona, 85724-5030, United States

Location

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

DNA, serum, supernatants

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveEmphysemaBronchitis, ChronicInflammation

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBronchitisRespiratory Tract InfectionsInfectionsBronchial Diseases

Study Officials

  • Stefano Guerra, MD, PhD

    Arizona Respiratory Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Research Professor

Study Record Dates

First Submitted

October 31, 2006

First Posted

November 2, 2006

Study Start

July 1, 2006

Primary Completion

January 1, 2013

Study Completion

January 1, 2013

Last Updated

December 6, 2017

Record last verified: 2017-12

Locations

US(1)